Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Rosenberg

Vascular & Interventional Radiology Minneapolis, MN Medical Doctor

NPI 1023097755 CMS profile 772

909 Fulton St Se, Ste 140, Minneapolis, MN 55455

Open in the dashboard

General payments

$134,134

145 records reported · program years 2019–2025

Research payments

$22,975

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$69,663 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Michael Rosenberg of Minneapolis, MN is reported in the CMS Open Payments database as having received $134,134 across 145 general payments and $22,975 in research payments paid to them. Separately, studies naming them as principal investigator received $69,663 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,497 19
2024 General $19,117 11
2024 Research $4,875 1
2023 General $24,680 19
2023 Research $5,500 3
2022 General $19,262 25
2022 Research $3,000 2
2021 General $25,597 22
2021 Research $5,850 3
2020 General $17,908 13
2019 General $16,072 36
2019 Research $3,750 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Rosenberg
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Michael Rosenberg were reported at $11,497. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Michael Rosenberg Vascular & Interventional Radiology median Middle half National median
2019 $16,072 $422 $125–$1,555 $163
2020 $17,908 $200 $68–$652 $114
2021 $25,597 $280 $99–$866 $132
2022 $19,262 $433 $137–$1,497 $149
2023 $24,680 $506 $152–$2,019 $160
2024 $19,117 $556 $175–$1,930 $164
2025 $11,497 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $84,136 57 payments
  2. Medtronic Vascular, Inc. $19,850 10 payments
  3. Boston Scientific Corporation $11,504 20 payments
  4. Teleflex LLC $4,275 3 payments
  5. Penumbra, Inc. $3,940 20 payments
  6. AngioDynamics, Inc. $2,671 3 payments
  7. Surmodics, Inc. $2,634 4 payments
  8. Dova Pharmaceuticals $2,372 3 payments
  9. Bard Peripheral Vascular, Inc. $1,409 7 payments
  10. Abbott Laboratories $303 3 payments
  11. Other $1,041 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $111,188 61 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,125 4 payments
  3. Travel and Lodging $4,696 19 payments
  4. Food and Beverage $4,301 59 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,825 2 payments
Products named General payments · program years 2019–2025
  1. VENASEAL EndoVenous Therapies $18,035 9 payments
  2. Valiant Captivia $10,263 4 payments
  3. Heli-FX EndoAnchor System $8,650 5 payments
  4. Pacific $8,100 3 payments
  5. Reliant $6,063 3 payments
  6. Indigo $5,448 19 payments
  7. Sentrant $5,350 3 payments
  8. STEERANT $4,813 2 payments
  9. VenaSeal EndoVenous Therapies $4,275 2 payments
  10. MO.MA ULTRA $4,150 4 payments
  11. Other $49,736 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $19,225 9 payments
  2. Medtronic Vascular, Inc. $3,750 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Diagnostic Radiology: 24

Drug cost

$178

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 14 $178

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$118,818

Of which drugs: $622

Medicare patients

127

Average age 74

Services billed

2,917

72 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 47%
Diabetes 32%
Chronic kidney disease 31%
Ischemic heart disease 29%
Heart failure 26%
Atrial fibrillation 25%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 15 2,200 $228
Injection, midazolam hydrochloride, per 1 mg J2250 Office 12 38 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record